Skip to content

Study · Not a test of the peptide alone · 1994

5 results

Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats.

Rasi G, Silecchia G, Sinibaldi-Vallebona P, Spaziani E, Pierimarchi P, Sivilia M, Tremiterra S, Garaci E

International journal of cancer1 Jun 1994Cited by 33 (Europe PMC)

PMID8194879 (opens in a new tab)DOI10.1002/ijc.2910570516 (opens in a new tab)PepBankPUB-08194879
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with colorectal liver metastases, 5-FU followed by thymosin alpha‑1 and interleukin-2 significantly reduced the growth of liver metastases.

    In plain wordsIn rats with liver metastases, 5-FU followed by thymosin alpha‑1 and interleukin-2 slowed tumor growth.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseGrowth of liver metastases
    Study

    ratn: not reported in source

    BDIX rats with DHD/K12 colorectal liver metastases
    Comparator
    Control and other treatment groups
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Combined chemo-immunotherapy was shown both to significantly reduce the growth of liver metastases and to prevent extra-hepatic spread.
    2 context sentences
    Summary · context
    We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats.
    Summary · context
    Evaluable rats were assigned randomly to 5 experimental groups designated as control, 5-FU, IL-2, 5-FU/IL-2 and 5-FU/T alpha 1/IL-2.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with colorectal liver metastases, 5-FU followed by thymosin alpha‑1 and interleukin-2 prevented extra-hepatic spread.

    In plain wordsIn rats with liver metastases, 5-FU followed by thymosin alpha‑1 and interleukin-2 prevented spread outside the liver.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseExtra-hepatic spread
    Study

    ratn: not reported in source

    BDIX rats with DHD/K12 colorectal liver metastases
    Comparator
    Control and other treatment groups
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Combined chemo-immunotherapy was shown both to significantly reduce the growth of liver metastases and to prevent extra-hepatic spread.
    2 context sentences
    Summary · context
    We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats.
    Summary · context
    Evaluable rats were assigned randomly to 5 experimental groups designated as control, 5-FU, IL-2, 5-FU/IL-2 and 5-FU/T alpha 1/IL-2.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In rats with colorectal liver metastases, the regimen of 5-FU, thymosin alpha‑1 and interleukin-2 improved the survival rate.

    In plain wordsIn rats with liver metastases, a regimen of 5-FU, thymosin alpha‑1 and interleukin-2 improved survival.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival rate
    Study

    ratn: not reported in source

    BDIX rats with DHD/K12 colorectal liver metastases
    Comparator
    Control and other treatment groups
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    5-FU/T alpha 1/IL-2 also improved survival rate.
    2 context sentences
    Summary · context
    We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats.
    Summary · context
    Evaluable rats were assigned randomly to 5 experimental groups designated as control, 5-FU, IL-2, 5-FU/IL-2 and 5-FU/T alpha 1/IL-2.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In tumor-bearing or 5-FU immunodepressed rats, immunotherapy with thymosin alpha‑1 and interleukin-2 after 5-FU restored natural killer activity of blood mononuclear cells.

    In plain wordsIn rats, thymosin alpha‑1 and interleukin-2 given after 5-FU restored the killer-cell activity of blood immune cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseNK activity of PBMC
    Study

    ratn: not reported in source

    BDIX rats with DHD/K12 colorectal liver metastases
    Comparator
    Control and other treatment groups
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Combined immunotherapy after 5-FU restored NK activity of the peripheral-blood-mononuclear-cell (PBMC) in tumor and/or 5-FU immunodepressed rats and enhanced PBMC cytotoxic activity against the DHD/K12 autologous cell line.
    2 context sentences
    Summary · context
    We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats.
    Summary · context
    Evaluable rats were assigned randomly to 5 experimental groups designated as control, 5-FU, IL-2, 5-FU/IL-2 and 5-FU/T alpha 1/IL-2.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In rats, immunotherapy with thymosin alpha‑1 and interleukin-2 after 5-FU enhanced blood mononuclear cell cytotoxicity against the autologous DHD/K12 tumor cell line.

    In plain wordsIn rats, thymosin alpha‑1 and interleukin-2 given after 5-FU made blood immune cells kill more tumor cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePBMC cytotoxic activity against DHD/K12 cells
    Study

    ratn: not reported in source

    BDIX rats with DHD/K12 colorectal liver metastases
    Comparator
    Control and other treatment groups
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Combined immunotherapy after 5-FU restored NK activity of the peripheral-blood-mononuclear-cell (PBMC) in tumor and/or 5-FU immunodepressed rats and enhanced PBMC cytotoxic activity against the DHD/K12 autologous cell line.
    2 context sentences
    Summary · context
    We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats.
    Summary · context
    Evaluable rats were assigned randomly to 5 experimental groups designated as control, 5-FU, IL-2, 5-FU/IL-2 and 5-FU/T alpha 1/IL-2.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.